Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alight Study of add-on luseogliflozin to semaglutide in NASH with type 2 diabetes
jRCTs061210009Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of luseogliflozin and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM), sponsored by Taisho Pharmaceutical. Primary endpoints: Resolution of NASH without worsening of fibrosis, Improvement in NAFLD activity score without worsening of fibrosis and 1 more. Started Aug 2021; status: completed.
02
Drugs
luseogliflozinsemaglutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs061210009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210009.